Skip to Main Content
Sign In
Visit Apply Give

News Aniridia Foundation International

Image Picker for Section 0
Duncan lab awarded new two year grant from Aniridia Foundation International

​Edén et al. Cataract development in Norwegian patients with congenital aniridia. Acta Ophthalmol. 2014;92(2):165-167. doi:10.1111/aos.12225

​Aniridia is a genetic disease where children are born without the iris of their eye, and a retinal defect that reduces their baseline ability to see.  However, it is also unfortunately progressive, with patients developing cloudy corneas, glaucoma, retinal detachments and cataract.  While many of these conditions are treatable by surgery, these patients are also very prone to develop aggressive, difficult to treat, ocular scarring which can lead to total blindness as they age. 

Eye on Aniridia Newsletter

​Polar subcapsular cataract
Polar subcapsular cataract

​Edén et al. Cataract development in Norwegian patients with congenital aniridia. Acta Ophthalmol. 2014;92(2):165-167. doi:10.1111/aos.12225

​Anterior subcapsular cataract
Anterior subcapsular cataract

​Edén et al. Cataract development in Norwegian patients with congenital aniridia. Acta Ophthalmol. 2014;92(2):165-167. doi:10.1111/aos.12225


Both can eventually become ‘mature’
Mature Aniridia Eye

​​Edén et al. Cataract development in Norwegian patients with congenital aniridia. Acta Ophthalmol. 2014;92(2):165-167. doi:10.1111/aos.12225



​The Duncan lab has been working with Aniridia Foundation International (AFI) to understand the molecular mechanisms underlying this scarring with the goal of identifying new therapies able to maintain patient vision in the long term. Recent gene expression profiling of an animal model of aniridia has revealed a new potential mechanism of fibrotic disease in aniridia that could lead to new therapies.   AFI just funded a new two year award to Melinda Duncan's group to validate this molecular mechanism and to explore whether blocking these pathways could help aniridia patients retain their vision long term.

News Story Supporting Images and Text
Used in the Home Page News Listing and for the News Rollup Page
The Duncan lab has been working with Aniridia Foundation International (AFI) to understand the molecular mechanisms underlying this scarring with the goal of identifying new therapies able to maintain patient vision in the long term.

The Duncan lab has been working with AFI to understand the molecular mechanisms underlying this scarring with the goal of identifying new therapies able to maintain patient vision.

5/29/2020
Page Settings and MetaData:
(Not Shown on the Page)
Page Settings
Aniridia
 
No
 
 
MetaData for Search Engine Optimization
Aniridia Foundation International
 
  • Department of Biological Sciences
  • 105 The Grn, Room 118 Wolf Hall
  • Newark, DE 19716, USA
  • University of Delaware
  • Phone: 302-831-6977
  • bio-questions@udel.edu